A brief review on Pleiotropic effects of Pirfenidone - novel and ongoing outcomes

Authors

  • Ravishankar C Department of Pharmacology, Faculty of Pharmacy, Ramaiah University of Applied Sciences, Bangalore, 560054, India
  • Jaydeep Roy Department of Pharmacology, Faculty of Pharmacy, Ramaiah University of Applied Sciences, Bangalore, 560054, India
  • Damodar Nayak Ammunje Department of Pharmacology, Faculty of Pharmacy, Ramaiah University of Applied Sciences, Bangalore, 560054, India
  • J Anbu Department of Pharmacology, Faculty of Pharmacy, Ramaiah University of Applied Sciences, Bangalore, 560054, India
  • Mohammad Azamthulla Department of Pharmacology, Faculty of Pharmacy, Ramaiah University of Applied Sciences, Bangalore, 560054, India

DOI:

https://doi.org/10.21276/IJRDPL.2278-0238.2019.8(1).6-14

Keywords:

Pirfenidone (PFD), Anti-fibrotic, Anti-Inflammatory, Anti-oxidant, Idiopathic pulmonary fibrosis (IPF)

Abstract

Presently, there is a huge hype and excitement in the field of synthetic biologics and engineering regarding growing cases of their implication in various fields including health care systems. Furthermore, despite its large body of suggestive and fascinating accomplishments, the synthetic area is always been subject of much more prejudice and debate. However, over a couple of years, the generation of researchers had tested one of such disease modifying compound Pirfenidone (Esbriet®), to unleash their potential in the different disciplines of interventional pharmacology and therapy. In this pipeline, depending on its success of multiple missions, in context to advancing the therapy for different diseases, it became the first prescribed medicine to treat the people with one characteristic lung disorder called idiopathic pulmonary fibrosis (IPF). This review discusses the different therapeutic strategies beyond its well-known anti-fibrotic activity in several well-characterized animals, cell-based and human models and also regarding facts of Pirfenidone (PFD) as anti-inflammatory, anti-fibrinogenic, anti-oxidants including in the treatment of diabetic neuropathy, liver cirrhosis etc. This review also contains current investigations, focusing mainly on the novel findings and their outcomes in improving the quality of life of patients with different conditions and also suggests their implication on the basis of fundamental existential evidences to break the major impediment in transforming this disease-modifying drug into a personalized medicine.

Downloads

Download data is not yet available.

References

Buelna M, Sanchez-Enriquez S, Lucano-Landeros S, Macias-Barragan J, Armendariz-Borunda J. Role and new insights of pirfenidone in fibrotic diseases. International journal of medical sciences. 2015; 12(11):840

Loisance DY. Quality of life in advanced chronic heart failure: a relevant or a misleading parameter.

Parmar VK, Desai SB, Vaja T. RP-HPLC and UV spectrophotometric methods for estimation of pirfenidone in pharmaceutical formulations. Indian journal of pharmaceutical sciences. 2014; 76(3):225.

EMEA PN. CHMP assessment report. Evaluation. 2010.

Schaefer CJ, Ruhrmund DW, Pan L, Seiwert SD, Kossen K. Antifibrotic activities of pirfenidone in animal models. European Respiratory Review. 2011; 20(120):85-97.

Komiya C, Tanaka M, Tsuchiya K, Shimazu N, Mori K, Furuke S, Miyachi Y, Shiba K, Yamaguchi S, Ikeda K, Ochi K. Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis. Scientific reports. 2017; 7:44754.

Meléndez GC, McLarty JL, Levick SP, Du Y, Janicki JS, Brower GL. Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension. 2010; 56(2):225-31.

McCrudden R, Iredale JP. Invited Reviews-Liver fibrosis, the hepatic stellate cell and tissue inhibitors of metalloproteinases. Histology and histopathology. 2000; 15(4):1159-68.

Sharma K, Ix JH, Mathew AV, Cho M, Pflueger A, Dunn SR, Francos B, Sharma S, Falkner B, McGowan TA, Donohue M. Pirfenidone for diabetic nephropathy. Journal of the American Society of Nephrology. 2011; 22(6):1144-51.

Chen J, Lu MM, Liu B, Chen Z, Li QB, Tao LJ, Hu GY. Synthesis and structure-activity relationship of 5-substituent-2 (1H)-pyridone derivatives as anti-fibrosis agents. Bioorganic & medicinal chemistry letters. 2012; 22(6):2300-2.

Haak AJ, Girtman MA, Ali MF, Carmona EM, Limper AH, Tschumperlin DJ. Phenylpyrrolidine structural mimics of pirfenidone lacking antifibrotic activity: A new tool for mechanism of action studies. European journal of pharmacology. 2017; 811:87-92

Krishnan S, Goble JM, Frederick LA, James CD, Uhm JH, Kaufmann SH, Babovic-Vuksanovic D. Inhibitory effect of pirfenidone on glioblastoma cell lines: implications for treatment of neurofibromatosis. Journal of Applied Research. 2007; 7(1):58-69.

Molina-Molina M, Machahua-Huamani C, Vicens-Zygmunt V, Llatjós R, Escobar I, Sala-Llinas E, Luburich-Hernaiz P, Dorca J, Montes-Worboys A. Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells. BMC pulmonary medicine. 2018; 18(1):63

Myllärniemi M, Kaarteenaho R. Pharmacological treatment of idiopathic pulmonary fibrosis-preclinical and clinical studies of pirfenidone, nintedanib, and N-acetylcysteine. European clinical respiratory journal. 2015; 2(1):26385.

Lehtonen ST, Veijola A, Karvonen H, Lappi-Blanco E, Sormunen R, Korpela S, Zagai U, Sköld MC, Kaarteenaho R. Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis. Respiratory research. 2016; 17(1):14.

Hayton C, Chaudhuri N. Current treatments in the management of idiopathic pulmonary fibrosis: pirfenidone and nintedanib. Clinical Medicine Insights: Therapeutics. 2017; 9:1179559X17719126.

Lee BS, Margolin SB, Nowak RA. Pirfenidone: a novel pharmacological agent that inhibits leiomyoma cell proliferation and collagen production. The Journal of Clinical Endocrinology & Metabolism. 1998; 83(1):219-23.

Everett IV TH, Olgin JE. Atrial fibrosis and the mechanisms of atrial fibrillation. Heart Rhythm. 2007; 4(3): S24-7.

Mirkovic S, Seymour AM, Fenning A, Strachan A, Margolin SB, Taylor SM, Brown L. Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA?salt hypertensive rats. British journal of pharmacology. 2002; 135(4):961-8.

Nguyen DT, Ding C, Wilson E, Marcus GM, Olgin JE. Pirfenidone mitigates left ventricular fibrosis and dysfunction after myocardial infarction and reduces arrhythmias. Heart Rhythm. 2010; 7(10):1438-45.

Binkley PF, Nunziata E, Haas GJ, Nelson SD, Cody RJ. Parasympathetic withdrawal is an integral component of autonomic imbalance in congestive heart failure: demonstration in human subjects and verification in a paced canine model of ventricular failure. Journal of the American College of Cardiology. 1991; 18(2):464-72.

Leong DP, Madsen PL, Selvanayagam JB. Non-invasive evaluation of myocardial fibrosis: implications for the clinician. Heart. 2010; 96(24):2016-24.

Lee BS, Margolin SB, Nowak RA. Pirfenidone: a novel pharmacological agent that inhibits leiomyoma cell proliferation and collagen production. The Journal of Clinical Endocrinology & Metabolism. 1998; 83(1):219-23.

Yamagami K, Oka T, Wang Q, Ishizu T, Lee JK, Miwa K, Akazawa H, Naito AT, Sakata Y, Komuro I. Pirfenidone Exhibits Cardioprotective Effects by Regulating Myocardial Fibrosis and Vascular Permeability in Pressure Overloaded Hearts. American Journal of Physiology-Heart and Circulatory Physiology. 2015.

Wang Y, Wu Y, Chen J, Zhao S, Li H. Pirfenidone attenuates cardiac fibrosis in a mouse model of TAC-induced left ventricular remodeling by suppressing NLRP3 inflammasome formation. Cardiology. 2013; 126(1):1-1.

Shi Q, Liu X, Bai Y, Cui C, Li J, Li Y, Hu S, Wei Y. In vitro effects of pirfenidone on cardiac fibroblasts: proliferation, myofibroblast differentiation, migration and cytokine secretion. PloS one. 2011; 6(11):e28134.

Liu H, Drew P, Gaugler AC, Cheng Y, Visner GA. Pirfenidone Inhibits Lung Allograft Fibrosis through L?Arginine-Arginase Pathway. American Journal of Transplantation. 2005; 5(6):1256-63.

Spond J, Case N, Chapman RW, Crawley Y, Egan RW, Fine J, Hey JA, Kreutner W, Kung T, Wang P, Minnicozzi M. Inhibition of experimental acute pulmonary inflammation by pirfenidone. Pulmonary pharmacology & therapeutics. 2003; 16(4):207-14

Claussen CA, Long EC. Nucleic acid recognition by metal complexes of bleomycin. Chemical reviews. 1999; 99(9):2797-816

Fleischman RW, Baker JR., Thompson GR., Schaeppi UH, Illievski VR., Cooney DA and Davis RD. Bleomycin-Induced Pulmonary Fibrosis in Dogs. Thorax 1971; 26: 675-68

Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis. The international journal of biochemistry & cell biology. 2008; 40(3):362-82.

Moller A, Rodriguez-Lecompte JC, Wang L, Gauldie J, Kolb M. Models of pulmonary fibrosis. 2006; 3(3): 243-249

Iyer SN, Hyde DM, Giri SN. Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation. Inflammation. 2000; 24(5):477-91.

Liu H, Drew P, Gaugler AC, Cheng Y, Visner GA. Pirfenidone Inhibits Lung Allograft Fibrosis through L?Arginine-Arginase Pathway. American Journal of Transplantation. 2005; 5(6):1256-63.

Zhou XM, Zhang GC, Li JX, Hou J. Inhibitory effects of Hu-qi-yin on the bleomycin-induced pulmonary fibrosis in rats. Journal of ethnopharmacology. 2007; 111(2):255-64.

Nakayama S, Mukae H, Sakamoto N, Kakugawa T, Yoshioka S, Soda H, Oku H, Urata Y, Kondo T, Kubota H, Nagata K. Pirfenidone inhibits the expression of HSP47 in TGF-β1-stimulated human lung fibroblasts. Life sciences. 2008; 82 (3-4):210-7.

Shimizu T, Fukagawa M, Kuroda T, Hata S, Iwasaki Y, Nemoto M, Shirai K, Yamauchi S, Margolin SB, Shimizu F, Kurokawa K. Pirfenidone prevents collagen accumulation in the remnant kidney in rats with partial nephrectomy. Kidney International Supplement. 1997; (63).

Oku H, Shimizu T, Kawabata T, Nagira M, Hikita I, Ueyama A, Matsushima S, Torii M, Arimura A. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. European journal of pharmacology. 2008; 590(1-3):400-8.

Macías-Barragán J, Sandoval-Rodríguez A, Navarro-Partida J, Armendáriz-Borunda J. The multifaceted role of pirfenidone and its novel targets. Fibrogenesis & tissue repair. 2010; 3(1):16.

Salazar-Montes A, Ruiz-Corro L, López-Reyes A, Castrejón-Gómez E, Armendáriz-Borunda J. Potent antioxidant role of pirfenidone in experimental cirrhosis. European journal of pharmacology. 2008; 595(1-3):69-77.

Di Sario A, Bendia E, Baroni GS, Ridolfi F, Casini A, Ceni E, Saccomanno S, Marzioni M, Trozzi L, Sterpetti P, Taffetani S. Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production. Journal of hepatology. 2002; 37(5):584-91.

Misra HP, Rabideau C. Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals. Molecular and cellular biochemistry. 2000; 204(1-2):119-26.

A Bioequivalence Study Comparing Pirfenidone Tablet and Capsule Dosage Forms in Healthy Adult Participants - Full Text View - ClinicalTrials.gov [Internet]. Clinicaltrials.gov. 2019 [cited 14 March 2019]. Available from: https://clinicaltrials.gov/ct2/show/NCT02525484 .

Pirfenidone in Treating Young Patients with Neurofibromatosis Type 1 and Plexiform Neurofibromas - Full Text View - ClinicalTrials.gov [Internet]. Clinicaltrials.gov. 2019 [cited 14 March 2019]. Available from: https://clinicaltrials.gov/ct2/show/NCT00053937.

A Study of Oral Vismodegib in Combination with Pirfenidone in Participants with Idiopathic Pulmonary Fibrosis - Full Text View - ClinicalTrials.gov [Internet]. Clinicaltrials.gov. 2019 [cited 14 March 2019]. Available from: https://clinicaltrials.gov/ct2/show/NCT02648048.

Pirfenidone Combined with Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC - Full Text View - ClinicalTrials.gov [Internet]. Clinicaltrials.gov. 2019 [cited 14 March 2019]. Available from: https://clinicaltrials.gov/ct2/show/NCT03177291.

The Safety and Tolerability of Pirfenidone for BOS after HCT - Full Text View - ClinicalTrials.gov [Internet]. Clinicaltrials.gov. 2019 [cited 14 March 2019]. Available from: https://clinicaltrials.gov/ct2/show/NCT03315741.

Pirfenidone Completed Phase 1 / 2 Trials for Chronic Kidney Disease (CKD) / Fibrosis Treatment - DrugBank [Internet]. Drugbank.ca. 2019 [cited 14 March 2019]. Available from: https://www.drugbank.ca/drugs/DB04951/clinical_trials?conditions=DBCOND0048800%2CDBCOND0012375&phase=1%2C2&purpose=treatment&status=completed.

Pirfenidone Completed Phase 1 / 2 Trials for Diabetic Nephropathies / Diabetes Mellitus (DM) Treatment - DrugBank [Internet]. Drugbank.ca. 2019 [cited 14 March 2019]. Available from: https://www.drugbank.ca/drugs/DB04951/clinical_trials?conditions=DBCOND0063084%2CDBCOND0000983&phase=1%2C2&purpose=treatment&status=completed.

Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome - Full Text View - ClinicalTrials.gov [Internet]. Clinicaltrials.gov. 2019 [cited 14 March 2019]. Available from: https://clinicaltrials.gov/ct2/show/NCT00001596.

Pirfenidone, an Antifibrotic and Antiinflammatory Drug - Full Text View - ClinicalTrials.gov [Internet]. Clinicaltrials.gov. 2019 [cited 14 March 2019]. Available from: https://clinicaltrials.gov/ct2/show/NCT02161952.

Pirfenidone to Treat Hypertrophic Cardiomyopathy - Full Text View - ClinicalTrials.gov [Internet]. Clinicaltrials.gov. 2019 [cited 14 March 2019]. Available from: https://clinicaltrials.gov/ct2/show/NCT00011076.

How to cite this article:

Ravishankar C, Roy J, Ammunje DN, Anbu J and Azamthulla M. A brief review on Pleiotropic effects of Pirfenidone - novel and ongoing outcomes. Int. J. Res. Dev. Pharm. L. Sci. 2019; 8(1): 6-14. doi: 10.13040/IJRDPL.2278-0238.8(1).6-14

This Journal is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

Published

2019-01-15

How to Cite

C , R. ., Roy, J. ., Ammunje, D. N. ., Anbu, . J. ., & Azamthulla, M. (2019). A brief review on Pleiotropic effects of Pirfenidone - novel and ongoing outcomes. International Journal of Research and Development in Pharmacy & Life Sciences, 8(1), 06-14. https://doi.org/10.21276/IJRDPL.2278-0238.2019.8(1).6-14